Sarcopenia and obesity: Two sides of the same coin. Incretin technologies in addressing the problem
https://doi.org/10.62751/2713-0177-2025-6-4-06
Abstract
Obesity has become one of the most serious health problems in the 21st century, affecting millions of people worldwide (approximately 42–43% of the adult population). However, there is a tendency to increase life expectancy in the world, which inevitably increases the frequency of comorbid pathology, one of which is sarcopenia. According to international experts, sarcopenia will become a global problem by 2045. The urgency of the problem of sarcopenic obesity is due to the steadily increasing prevalence of obesity worldwide. An important aspect that is often overlooked in the context of combating obesity is the preservation of muscle mass, which plays a key role in maintaining health and quality of life. The purpose of our review is to analyze data on the effect of modern drugs such as tirzepatide and semaglutide on muscle tissue.
About the Authors
T. Yu. Demidova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tatiana Yu. Demidova – D. Sci. (Med.), Prof., Head of the Department of Endocrinology, Institute of Clinical Medicine
Moscow
K. A. Tolmacheva
City Clinical Hospital № 2 named after E. G. Lazarev
Russian Federation
Russian Federation
Kira A. Tolmacheva – endocrinologist
Tula
S. A. Prilepa
Tula State University
Russian Federation
Russian Federation
Svetlana A. Prilepa – C. Sci. (Med.), Lecturer in the Department of Internal Medicine, Medical Institute
Tula
References
1. World Health Organization. Obesity and overweight 2024. 2024. URL: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (date of access – 26.11.2025).
2. Lingvay I, Cohen RV, Roux CWL, Sumithran P. Obesity in adults. Lancet. 2024;404(10456):972–87. doi: 10.1016/S0140-6736(24)01210-8.
3. Клинические рекомендации. Ожирение. Российская ассоциация эндокринологов, Общество бариатрических хирургов. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 28_3. Доступ: https://cr.minzdrav.gov.ru/view-cr/28_3 (дата обращения – 26.11.2025).
4. Toptas M, Yalcin M, Akkoc İ, Demir E, Metin C, Savas Y et al. The relation between sarcopenia and mortality in patients at intensive care unit. Biomed Res Int. 2018;2018:5263208. doi: 10.1155/2018/5263208.
5. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyere O. Health outcomes of sarcopenia: A systematic review and meta-analysis. PLoS One. 2017;12(1):e0169548. doi: 10.1371/journal.pone.0169548.
6. Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022;15(3):321–35. doi: 10.1159/000521241.
7. Silva TL, Mulder AP. Sarcopenia and poor muscle quality associated with severe obesity in young adults and middleaged adults. Clin Nutr ESPEN. 2021;45:299–305. doi: 10.1016/j.clnesp.2021.07.031.
8. Wagenaar CA, Dekker LH, Navis GJ. Prevalence of sarcopenic obesity and sarcopenic overweight in the general population: The lifelines cohort study. Clin Nutr. 2021;40(6):4422–29. doi: 10.1016/j.clnu.2021.01.005
9. Zembura M, Matusik P. Sarcopenic obesity in children and adolescents: A systematic review. Front Endocrinol (Lausanne). 2022;13:914740. doi: 10.3389/fendo.2022.914740.
10. Wang M, Tan Y, Shi Y, Wang X, Liao Z, Wei P. Diabetes and sarcopenic obesity: Pathogenesis, diagnosis, and treatments. Front Endocrinol (Lausanne). 2020;11:568. doi: 10.3389/fendo.2020.00568.
11. Wei S, Nguyen TT, Zhang Y, Ryu D, Gariani K. Sarcopenic obesity: Epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol (Lausanne). 2023;14:1185221. doi: 10.3389/fendo.2023.1185221.
12. Christoffersen B, Sanchez-Delgado G, John LM, Ryan DH, Raun K, Ravussin E. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity (Silver Spring). 2022;30(4):841–57. doi: 10.1002/oby.23374.
13. Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab. 2011;96(9):2898–903. doi: 10.1210/jc.2011-0435.
14. Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab (Seoul). 2019;34(3):247–62. doi: 10.3803/EnM.2019.34.3.247.
15. Xu Q, Qiu X, Di H, Li Z, Liu Z, Liu K. Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway. J Diabetes Complicat. 2025;39(3):108975. doi: 10.1016/j.jdiacomp.2025.108975.
16. Wu L, Zhou M, Li T, Dong N, Yi L, Zhang Q, Mi M. GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway. Biochim Biophys Acta Mol Cell Res. 2022;1869(9):119300. doi: 10.1016/j.bbamcr.2022.119300.
17. Xiang J, Qin L, Zhong J, Xia N, Liang Y. GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes. 2023;16:2433–46. doi: 10.2147/DMSO.S425642.
18. Mastaitis JW, Gomez D, Raya JG, Li D, Min S, Stec M et al. GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nat. Commun. 2025;16(1):4377. doi: 10.1038/s41467-025-59485-9.
19. Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049–57. doi: 10.1038/s41591-024-02996-7.
20. Kushner R, Aronne L, Stefanski A, Ahmad N, Mao H, Bunck M et al. Tirzepatide-induced weight loss is associated with body composition improvements across age groups. Obesity (Silver Spring). 2022;30:49. doi: 10.1002/oby.23625.
21. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989. doi: 10.1056/NEJMoa2032183.
22. McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, Lingvay I. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63(3):473–85. doi: 10.1007/s00125-019-05065-8.
23. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389(12):1069–84. doi: 10.1056/NEJMoa2306963.
24. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK et al.; STEPHFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesityrelated heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394–407. doi: 10.1056/NEJMoa2313917.
25. Rubino D, Bjorner JB, Rathor N, Sharma AM, von Huth Smith L, Wharton S et al. Effect of semaglutide 2.4mg on physical functioning and weight- and healthrelated quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1–4 trials. Diabetes Obes Metab 2024;26(7):2945–55. doi: 10.1111/dom.15620.
26. Anyiam O, Ardavani A, Rashid RSA, Panesar A, Idris I. How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis. Obes Rev. 2025;26(7):e13916. doi: 10.1111/obr.13916.
27. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113.doi: 10.1016/j.metabol.2024.156113.
28. Alissou M, Demangeat T, Folope V, Van Elslande H, Lelandais H, Blanchemaison J et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112–121. doi: 10.1111/dom.70141.
29. Листок-вкладыш – информация для пациента. Семавик® Некст, 0,25 мг/ доза, раствор для подкожного введения. Семавик® Некст, 0,5 мг/доза, раствор для подкожного введения. Семавик® Некст, 1 мг/доза, раствор для подкожного введения. Семавик® Некст, 1,7 мг/доза, раствор для подкожного введения. Семавик® Некст, 2,4 мг/доза, раствор для подкожного введения. Соответствует экспертному отчету от 01.10.2024, № 21153 (последовательность 0002).
30. Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720–29. doi: 10.1111/dom.16275. Erratum in: Diabetes Obes Metab. 2025;27(11):6823. doi: 10.1111/dom.70050.
31. Луговик И.А., Бабина А.В., Арутюнян С.С., Ермолаева Д.О., Сапарова В.Б., Кобелева Т.Н. с соавт. Первый дженерик тирзепатида GP30931: физико-химическое и биологическое сходство с референтным лекарственным средством. Разработка и регистрация лекарственных средств. 2025;14(2):54–74. doi: 10.33380/2305-2066-2025-14-2-2084.
32. Ryan DH. New drugs for the treatment of obesity: Do we need approaches to preserve muscle mass? Rev Endocr Metab Disord. 2025;26(5):805–13. doi: 10.1007/s11154-025-09967-4.
33. New obesity drug RES-010 targets metabolism to prevent weight regain. URL: https://www.drugtargetreview.com/news/187995/new-obesity-drug-res-010-targetsmetabolism-to-prevent-weight-regain/ (date of access – 26.11.2025).
34. Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 2021;384(18):1719–30. doi: 10.1056/NEJMoa2028198.
35. Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism. 2024;161:156057. doi: 10.1016/j.metabol.2024.156057.
36. Prado CM, Batsis JA, Donini LM, Gonzalez MC, Siervo M. Sarcopenic obesity in older adults: A clinical overview. Nat Rev Endocrinol. 2024;20(5):261–77. doi: 10.1038/s41574-023-00943-z.
37. Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105. doi: 10.1111/dom.14551.
Review
For citations:
Demidova T.Yu., Tolmacheva K.A., Prilepa S.A. Sarcopenia and obesity: Two sides of the same coin. Incretin technologies in addressing the problem. FOCUS. Endocrinology. 2025;6(4):43-54. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-4-06
Views:
71
JATS XML
Email this article 